

Rutgers Cancer Institute of New Jersey





Clinical Trials Connection

A Cancer Resource for Healthcare Professionals

Fall 2016

[Resources for Physicians](#)

 [Send to a Colleague](#)

 [Join Our Mailing List](#)



Usha Malhotra, MD

is a medical oncologist in the Gastrointestinal/Hepatobiliary Oncology Program at Rutgers Cancer Institute of New Jersey, and an assistant professor of medicine at Rutgers Robert Wood Johnson Medical School, providing comprehensive care to those with colorectal, pancreatic, stomach and other gastrointestinal malignancies.

Contact Dr. Malhotra:
um49@cinj.rutgers.edu
732-235-8975

Clinical Trial Spotlight

Precision Medicine Clinical Trials

Rutgers Cancer Institute is offering a variety of clinical trials

Gastrointestinal / Hepatobiliary Oncology Clinical Trials

[View printable version](#)

MK-3475-062: A Randomized, Active-Controlled, Partially Blinded, Biomarker Select, Phase III Clinical Trial of Pembrolizumab as Monotherapy and in Combination with Cisplatin+5-Fluorouracil Versus Placebo+ Cisplatin+5-Fluorouracil as First-Line Treatment in Subjects with Advanced Gastric or Gastroesophageal Junction (GEJ) Adenocarcinoma

The study aims to:

- Compare progression free survival (PFS) per RECIST 1.1 as assessed by blinded central radiologists' review.
- Compare overall survival (OS).

[Learn more about this trial](#)

A Phase III Study of Pembrolizumab (MK-3475) vs. Standard of Care Chemotherapy in Microsatellite Instability-High (MSI-H) or Mismatch Repair Deficient (dMMR) Stage IV Colorectal Carcinoma (KEYNOTE-177)

The study aims to:

- Compare progression free survival (PFS).
- Compare overall response rate (ORR).
- Compare overall survival.

[Learn more about this trial](#)

that focus on genomic analysis and precision medicine efforts, including treatment for rare and poor prognosis cancers and more common malignancies.

[Learn more about these trials](#)

Other Available Trials

[Breast](#)

[Gastrointestinal/
Hepatobiliary](#)

[Gynecologic](#)

[Hematologic Oncology](#)

[Melanoma](#)

[Pediatric](#)

[Phase I](#)

[Prostate](#)

[Thoracic](#)



COG AHEP0731: Treatment of Children with All Stages of Hepatoblastoma

The study aims to:

- Estimate the EFS in children with Stage I (non-PFH, non-SCU) and Stage II (non SCU) hepatoblastoma treated with surgical resection followed by 2 cycles of C5V.
- Determine the feasibility and toxicity of adding doxorubicin to the chemotherapy regimen of C5V for children with intermediate-risk hepatoblastoma.
- Estimate the response rate to vincristine and irinotecan in previously untreated children with high-risk, metastatic hepatoblastoma.
- Determine whether timely (between diagnosis and end of second cycle of chemotherapy) consultation with a treatment center with surgical expertise in major pediatric liver resection and transplant can be achieved in 70% of patients with potentially unresectable hepatoblastoma.

[Learn more about this trial](#)



As New Jersey's only National Cancer Institute-designated Comprehensive Cancer Center, Rutgers Cancer Institute of New Jersey offers patients access to treatment options not available at other institutions within the state. The Cancer Institute currently enrolls approximately 17 percent of all new adult cancer patients and approximately 70 percent of all pediatric cancer patients onto a clinical trial. Enrollment in these studies

nationwide is fewer than five percent of all adult cancer patients.

[Learn more](#)

Cancer Institute of New Jersey, Rutgers, The State University of New Jersey,
195 Little Albany St., New Brunswick, NJ 08903